Ticker

Coloplast is now a clear Buy, trading nearly 60% below its all-time high and at historically low valuation multiples. CLPBF's wide economic moat, underpinned by patents and high switching costs, supports stable, mid-to-high single-digit growth expectations for the long term. Management targets 7–8% organic revenue growth and at least 20% ROIC by FY 2029/30, with current dividend yield above 5% but payout ratio…

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons.

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons

Announcement no. 3/2026 Inside information Coloplast appoints Gavin Wood as new CEO The Coloplast Board of Directors is pleased to announce the appointment of Gavin Wood as the new President and Chief Executive Officer (CEO) of the Coloplast Group, effective May 1, 2026.

Please see enclosed pdf. Update to Financial Calendar Dates Coloplast has updated the dates in its financial calendar for the publication of the FY Financial Statements 2025/26 and the Annual General Meeting 2026.